Contact
searchSearch
HMP Global
Login

News

News
Ivonescimab Plus Liposomal Irinotecan Demonstrates Second-Line Promise in Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
Ivonescimab Plus Liposomal Irinotecan Demonstrates Second-Line Promise in Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
177Lu-Satoreotide Tetraxetan Shows Strong Preliminary Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1...
06/09/2026
Oncology
News
177Lu-Satoreotide Tetraxetan Shows Strong Preliminary Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1...
06/09/2026
Oncology
News
Autologous NK Cell Consolidation Improves Survival Outcomes in Limited-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
Autologous NK Cell Consolidation Improves Survival Outcomes in Limited-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Oligoprogression Predicts Improved Survival After Chemoimmunotherapy in Relapsed Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory SCLC who have a short chemotherapy-free interval.
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory SCLC who have a short chemotherapy-free interval.
Results from a phase 2 trial...
04/02/2026
Oncology

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use